Janney Capital Starts uniQure BV (QURE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Chardan Capital Says uniQure (QURE) on Pullback, Slight Delay to AMT-060 is Immaterial
December 1, 2015 10:04 AM ESTChardan Capital affirms its Buy rating and $40 price target on uniQure N.V. (Nasdaq: QURE) following the company's Q3 report and update issued on Monday.
Analyst Gbola Amusa says investors should buy on post-Q3 weakness. The analyst noted the following key points from the company's quarterly conference call:
AMT-060 (hemophilia B): In early January 2016 (previously due by end-2015), uniQure will release preliminary, top-line data for 2 patients who have completed at least 12 weeks of treatment, with full results from the first cohort of 5 patients at a scientific conference... MoreuniQure (QURE) Ests and PT Cut After Dropping Glybera - Jefferies
December 1, 2015 9:49 AM ESTJefferies analyst, Eun Yang, reduced the price target on uniQure BV (NASDAQ: QURE) to $36 vs $40 previously. The drop takes into account the loss of revenue from the removal of Glybera and increasing the discount rate to 13% (from 12%) to reflect yet-to-be proven commercial potential/success of gene therapy products. No change to... More
uniQure BV (QURE) Sell-Off 'Unfounded' - Oppenheimer
December 1, 2015 7:11 AM ESTOppenheimer Christopher Marai views yesterday's nearly 17% sell-off in uniQure BV (NASDAQ: QURE) unfounded. As such, the firm reiterated an Outperform rating and price target of $50.
uniQure reported 3Q15, ending the quarter with $215M in cash.
Marai commented, "Importantly, QURE clarified the... More
